BiotechTube
Innoviva Specialty Therapeutics

Innoviva Specialty Therapeutics

Burlingame, United States· Est.
innovivaspecialtytherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc. (NASDAQ: INVA), is a mission-driven biotech focused on addressing high unmet medical needs in critical care and infectious diseases through a strategic asset-centric model. The company has built a portfolio of five marketed products and a late-stage pipeline via targeted acquisitions and in-licensing, followed by expert development and commercialization. Its commitment to combating antimicrobial resistance was externally validated by a top-tier 80% performance rating in the 2026 Access to Medicine Foundation's AMR Benchmark Report.

Critical CareInfectious Diseases

Technology Platform

A strategic business development and asset optimization platform focused on in-licensing and acquiring clinical-stage or commercial small molecule assets, followed by expert late-stage development, formulation, regulatory strategy, and commercialization.

Opportunities

The growing global AMR crisis creates an urgent need for novel antibiotics, supported by increasing policy focus and potential pull incentives like the PASTEUR Act.
The company's recognized leadership in access and stewardship positions it well for partnerships and tenders in global health.
Its commercial portfolio provides a revenue base to fund strategic acquisitions of new late-stage assets.

Risk Factors

The antibiotic market suffers from fundamental economic challenges, including stewardship-driven low usage volumes and reimbursement hurdles.
The company's growth is heavily dependent on the successful launch of recent products (XACDURO, NUZOLVENCE, ZEVTERA).
The core business model carries acquisition and integration risks, including the potential for overpaying or encountering unexpected development issues with in-licensed assets.

Competitive Landscape

Competes in hospital-based infectious diseases against large pharma (Pfizer, Merck) and specialized biopharma (Paratek, Melinta), and in critical care against generic vasopressors. Differentiation is achieved through a focused portfolio of modern, targeted antibiotics and a demonstrated commitment to global access and stewardship, as recognized by the AMR Benchmark.

More companies in Small Molecule Drugs →More companies in United States →